Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

NCT01163357 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Autologous Hematopoietic Stem Cell Transplant Recipient
Loss of Chromosome 17p
Plasma Cell Leukemia
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: bortezomib
DRUG: fludarabine phosphate
OTHER: melphalan
RADIATION: total marrow irradiation
DRUG: tacrolimus
DRUG: sirolimus
PROCEDURE: peripheral blood stem cell transplantation
OTHER: laboratory biomarker analysis

Sponsor

City of Hope Medical Center

Collaborators

[object Object]